Revolutionary Treatment for HER2 Positive Metastatic Breast Cancer

In a significant advancement for breast cancer therapy, the combination of ENHERTU® (fam-trastuzumab deruxtecan-nxki) and pertuzumab has been granted priority review status by the U.S. Food and Drug Administration (FDA). This decision, announced on September 24, 2025, aims to evaluate the use of this treatment as a first-line option for patients diagnosed with HER2 positive metastatic breast cancer.

HER2 positive breast cancer, characterized by an overexpression of the HER2 protein, accounts for approximately 20% of breast cancer cases. Patients with this type of cancer often face aggressive disease progression. The innovative combination of ENHERTU® and pertuzumab represents a hopeful new pathway for many patients, potentially changing the standard of care.

Understanding ENHERTU® and Pertuzumab

ENHERTU® is a targeted therapy developed by Daiichi Sankyo and AstraZeneca, designed specifically to address HER2 positive tumors. It works by delivering cytotoxic agents directly to cancer cells, minimizing harm to surrounding healthy tissues. Pertuzumab, on the other hand, is a monoclonal antibody that inhibits the HER2 signaling pathway, further aiding in the attack against cancerous cells.

Clinical trials have shown promising results for this combination therapy, demonstrating improved response rates and overall survival for patients. This review by the FDA is a crucial step towards making this treatment widely available.

Impact and Future Implications

The FDA’s priority review designation accelerates the evaluation process, potentially leading to faster access to this innovative treatment for patients in need. With around 20,640 new cases of HER2 positive breast cancer expected in the United States in 2025, timely access to effective therapies is critical.

As the medical community eagerly anticipates the FDA's final decision, the potential of ENHERTU® plus pertuzumab could redefine treatment protocols for breast cancer and set new standards in oncological care.

Fun Fact

Did you know? The HER2 protein was first discovered in the 1980s, making significant strides in breast cancer research possible over the last few decades!

Source: The Joplin Globe